

Resource Summary Report

Generated by [RRID](#) on Aug 23, 2026

hACE2

RRID:Addgene_1786

Type: Plasmid

Proper Citation

RRID:Addgene_1786

Plasmid Information

URL: <http://www.addgene.org/1786>

Proper Citation: RRID:Addgene_1786

Insert Name: Angiotensin-converting enzyme 2

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:14647384](#)

Vector Backbone Description: Backbone Marker:Invitrogen; Backbone Size:5428; Vector Backbone:pcDNA3.1(-); Vector Types:Mammalian Expression; Bacterial Resistance:Ampicillin

Comments: See author's map for more information.

Plasmid Name: hACE2

Record Creation Time: 20220422T222029+0000

Record Last Update: 20260815T081119+0000

Ratings and Alerts

No rating or validation information has been found for hACE2.

No alerts have been found for hACE2.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 55 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Li K, et al. (2025) Flavivirus-based bivalent nanoparticle vaccines induce neutralizing antibodies and Th1 responses against flavivirus and coupling antigens. *iScience*, 28(11), 113659.

Gawriljuk VO, et al. (2025) Screening of Medicines for Malaria Venture Open Boxes Identifies Potent SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors. *ACS omega*, 10(37), 42711.

Bednash JS, et al. (2023) Inhibiting the Deubiquitinase UCHL1 Reduces SARS-CoV-2 Viral Uptake by ACE2. *American journal of respiratory cell and molecular biology*, 68(5), 566.

Luo SY, et al. (2023) Identification of Human Host Substrates of the SARS-CoV-2 Mpro and PLpro Using Subtiligase N-Terminomics. *ACS infectious diseases*, 9(4), 749.

Baggen J, et al. (2023) TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry. *Cell*, 186(16), 3427.

Mahalingam G, et al. (2023) Correlating the differences in the receptor binding domain of SARS-CoV-2 spike variants on their interactions with human ACE2 receptor. *Scientific reports*, 13(1), 8743.

García-Murria MJ, et al. (2023) Identification of small molecules capable of enhancing viral membrane fusion. *Virology journal*, 20(1), 99.

Oh CK, et al. (2023) Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection. *Nature chemical biology*, 19(3), 275.

Raymonda MH, et al. (2022) Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro. *Virology*, 566, 60.

Lee RK, et al. (2022) Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2. *International journal of molecular sciences*, 23(7).

Lee SY, et al. (2022) Construction of SARS-CoV-2 spike-pseudotyped retroviral vector inducing syncytia formation. *Virus genes*, 58(3), 172.

Liu J, et al. (2022) Integrin mediates cell entry of the SARS-CoV-2 virus independent of cellular receptor ACE2. *The Journal of biological chemistry*, 298(3), 101710.

Mannar D, et al. (2022) SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization. *Nature communications*, 13(1), 4696.

Aggarwal A, et al. (2022) Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia. *Nature microbiology*, 7(6), 896.

Ashhurst AS, et al. (2022) Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L. *Journal of medicinal chemistry*, 65(4), 2956.

Balachandran H, et al. (2022) Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses. *Cell reports*, 38(6), 110345.

Cui Q, et al. (2022) Compound screen identifies the small molecule Q34 as an inhibitor of SARS-CoV-2 infection. *iScience*, 25(1), 103684.

Harte JV, et al. (2022) Metalloprotease-Dependent S2'-Activation Promotes Cell-Cell Fusion and Syncytiation of SARS-CoV-2. *Viruses*, 14(10).

Clark NM, et al. (2022) Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection. *PloS one*, 17(3), e0257930.

Kim HK, et al. (2022) Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS-CoV-2 infection. *Journal of extracellular vesicles*, 11(1), e12179.